Rivaroxaban Anticoagulation for Superficial Vein Thrombosis

Summary

This is a Phase III, randomized, placebo controlled, blinded, parallel two arm, multicentre trial that will compare rivaroxaban 10mg daily with placebo in patients with symptomatic leg Superficial Vein Thrombosis (\> or = 5cm) that otherwise would not initially be treated with anticoagulant therapy.

Timeline

Start

2014-11-11

Primary completion

2018-12-03

Completion

2018-12-03

Drugs

Indications